These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 16775949)

  • 41. Immunization against Japanese encephalitis in China: a policy analysis.
    Liu W; Clemens JD; Yang JY; Xu ZY
    Vaccine; 2006 Jun; 24(24):5178-82. PubMed ID: 16697091
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunological equivalence between mouse brain-derived and Vero cell-derived Japanese encephalitis vaccines.
    Abe M; Shiosaki K; Hammar L; Sonoda K; Xing L; Kuzuhara S; Kino Y; Holland Cheng R
    Virus Res; 2006 Nov; 121(2):152-60. PubMed ID: 16815584
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bacterially expressed recombinant envelope protein domain III of Japanese encephalitis virus (rJEV-DIII) elicits Th1 type of immune response in BALB/c mice.
    Verma SK; Kumar S; Gupta N; Vedi S; Bhattacharya SM; Lakshmana Rao PV
    Vaccine; 2009 Nov; 27(49):6905-9. PubMed ID: 19761840
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Promise of new Japanese encephalitis vaccines.
    Fischer M; Casey C; Chen RT
    Lancet; 2007 Dec; 370(9602):1806-8. PubMed ID: 18061040
    [No Abstract]   [Full Text] [Related]  

  • 45. Immunomodulation of Japanese encephalitis vaccine through CpG oligodeoxynucleotides in mice.
    Sidhapuriwala JN; Sivalingam SP; Lu J; Moochhala SM
    Scand J Immunol; 2006 Oct; 64(4):370-5. PubMed ID: 16970676
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Construction and evaluation of a chimeric pseudoinfectious virus vaccine to prevent Japanese encephalitis.
    Ishikawa T; Widman DG; Bourne N; Konishi E; Mason PW
    Vaccine; 2008 May; 26(22):2772-81. PubMed ID: 18433947
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Past, present, and future of Japanese encephalitis.
    Hills SL; Phillips DC
    Emerg Infect Dis; 2009 Aug; 15(8):1333. PubMed ID: 19751614
    [No Abstract]   [Full Text] [Related]  

  • 48. Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants.
    Gatchalian S; Yao Y; Zhou B; Zhang L; Yoksan S; Kelly K; Neuzil KM; Yaïch M; Jacobson J
    Vaccine; 2008 Apr; 26(18):2234-41. PubMed ID: 18394765
    [TBL] [Abstract][Full Text] [Related]  

  • 49. IC-51, an injectable vaccine for the prevention of Japanese encephalitis virus infection.
    Jones T
    Curr Opin Mol Ther; 2009 Feb; 11(1):90-6. PubMed ID: 19169964
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Acute flaccid paralysis as an unusual presenting symptom of Japanese encephalitis: a case report and review of the literature.
    Chung CC; Lee SS; Chen YS; Tsai HC; Wann SR; Kao CH; Liu YC
    Infection; 2007 Feb; 35(1):30-2. PubMed ID: 17297587
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Japanese encephalitis vaccine cost: a major reason to be vaccinated in Bali.
    Wirawan IMA
    J Travel Med; 2021 Jul; 28(5):. PubMed ID: 33772281
    [No Abstract]   [Full Text] [Related]  

  • 52. A strategic plan for Japanese encephalitis control by 2015.
    Elias C; Okwo-Bele JM; Fischer M
    Lancet Infect Dis; 2009 Jan; 9(1):7. PubMed ID: 19095192
    [No Abstract]   [Full Text] [Related]  

  • 53. Epidemiology and burden of disease from Japanese encephalitis in Cambodia: results from two years of sentinel surveillance.
    Touch S; Hills S; Sokhal B; Samnang C; Sovann L; Khieu V; Soeung SC; Toda K; Robinson J; Grundy J
    Trop Med Int Health; 2009 Nov; 14(11):1365-73. PubMed ID: 19747185
    [TBL] [Abstract][Full Text] [Related]  

  • 54. WHO informal consultation on the scientific basis of specifications for production and control of inactivated Japanese encephalitis vaccines for human use, Geneva, Switzerland, 1-2 June 2006.
    Ferguson M; Kurane I; Wimalaratne O; Shin J; Wood D;
    Vaccine; 2007 Jul; 25(29):5233-43. PubMed ID: 17590244
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Japanese encephalitis for a reference to international travelers.
    Oya A; Kurane I
    J Travel Med; 2007; 14(4):259-68. PubMed ID: 17617849
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Japanese encephalitis vaccine: is it being sufficiently used in travellers?
    Geraghty CM; McCarthy JS
    Med J Aust; 2004 Sep; 181(5):269-70. PubMed ID: 15347277
    [No Abstract]   [Full Text] [Related]  

  • 57. Etiological structure of acute encephalitis in children and immunization program concerns at The National Hospital of PaediatricS in Vietnam.
    An PN; Huong TT
    Southeast Asian J Trop Med Public Health; 2014; 45 Suppl 1():37-9. PubMed ID: 25423786
    [No Abstract]   [Full Text] [Related]  

  • 58. Different contribution of co-stimulatory molecules B7.1 and B7.2 to the immune response to recombinant modified vaccinia virus ankara vaccine expressing prM/E proteins of Japanese encephalitis virus and two hepatitis B virus vaccines.
    NAM JH; BANG HS; CHO HW; CHUNG YH
    Acta Virol; 2007; 51(2):125-30. PubMed ID: 17900219
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Failure of Japanese encephalitis vaccine and infection in inducing neutralizing antibodies against West Nile virus, People's Republic of China.
    Tang F; Zhang JS; Liu W; Zhao QM; Zhang F; Wu XM; Yang H; Ly H; Cao WC
    Am J Trop Med Hyg; 2008 Jun; 78(6):999-1001. PubMed ID: 18541783
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of genomic variation in the challenge virus on the neutralization titres of recipients of inactivated JE vaccines--report of a collaborative study on PRNT50 assays for Japanese encephalitis virus (JE) antibodies.
    Ferguson M; Johnes S; Li L; Heath A; Barrett A
    Biologicals; 2008 Mar; 36(2):111-6. PubMed ID: 17892945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.